Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on LinkedIn:
“Plans for the long weekend?
Prepare for exciting insights at WCLC25!
With groundbreaking data on oncogene-driven NSCLC, it’s going to be a conference to remember!
Here are my top picks:
- Ivonescimab + Placebo vs Chemo in EGFR+ NSCLC (HARMONi)
- First-Line Osimertinib + Chemo in EGFRm Advanced NSCLC (FLAURA2)
- Zidesamtinib in ROS1+ Advanced/Metastatic NSCLC
- And much more!
Looking forward to hearing the results and exploring new options for treatment!”
More posts featuring Aakash Desai.